Combined amlexanox and anti-MCP-1 therapy suppresses tumor progression in a murine Lewis lung carcinoma model [0.03%]
联合使用氨鲁卡因和抗MCP-1治疗可抑制小鼠Lewis肺癌模型的肿瘤进展
Xiaodan Liu,Xue Dong,Jiaona Wei et al.
Xiaodan Liu et al.
This study aims to assess the effects of combined amlexanox and an antimonocyte chemoattractant protein-1 (MCP-1) mAb therapy in a murine Lewis lung carcinoma (LLC) model. A subcutaneous LLC model was established in mice, which were allocat...
First-line lorlatinib treatment in a 19-year-old patient with ALK-rearranged pulmonary large-cell neuroendocrine carcinoma: a case report and literature review [0.03%]
劳拉替尼一线治疗ALK重排的大细胞神经内分泌癌一例及文献复习
Fatih Kemik,Pinar Bulutay,Cevat İlteriş Kikili et al.
Fatih Kemik et al.
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive subtype of nonsmall cell lung cancer, typically occurring in elderly male smokers. Its occurrence in the adolescent population is exceptionally uncommon, with on...
The mTOR pathway inhibition with everolimus in pseudomyogenic hemangioendothelioma harboring SERPINE1-FOSB gene fusion: a case report and review of the literature [0.03%]
依维莫司靶向mTOR途径治疗SERPINE1-FOSB基因融合pseudo-myogenoid血管内皮细胞瘤一例并文献复习
Cevat İlteriş Kikili,Bahadir Köylü,Fatih Kemik et al.
Cevat İlteriş Kikili et al.
Pseudomyogenic hemangioendothelioma (PHE) is an extremely rare tumor that is frequently misdiagnosed as other vascular or soft tissue neoplasms and typically follows an indolent course. Due to its locally aggressive and multifocal nature, s...
FH-2001 is a novel FGFR/VEGFR dual inhibitor with immune-modulating activity [0.03%]
FH-2001是一种新型的FGFR/VEGFR双靶点抑制剂，并具有免疫调节作用
Aiguo Liu,Longfei Huang,Xin Gao et al.
Aiguo Liu et al.
Multiple cancers are driven by aberrant fibroblast growth factor receptor (FGFR) signaling and vascular endothelial growth factor receptor (VEGFR)-linked angiogenesis. Several therapeutic agents targeting FGFR and VEGFR have been developed ...
Exploring natural products for allosteric inhibition of glutathione peroxidase 4 in drug-resistant cancers via molecular docking and dynamics [0.03%]
基于分子对接与动力学模拟的药物抗性癌症中谷胱甘肽过氧化物酶4别构位点天然产物抑制剂的发现研究
Mohammad Yasir,Jeevan Patra,Rahul K Maurya et al.
Mohammad Yasir et al.
Glutathione peroxidase 4 (GPX4) plays a pivotal role in regulating ferroptosis and maintaining redox homeostasis, making it a critical target in drug-resistant cancers. Recent studies suggest that allosteric inhibition of GPX4 could overcom...
Discovery and optimization of oxidative phosphorylation inhibitors from a phenotypic screen [0.03%]
基于表型筛选的氧化磷酸化抑制剂的发现与优化
Mahmoud El Shemerly,Florian Richalet,Dimitri Robay et al.
Mahmoud El Shemerly et al.
Tumor metabolism and metabolic reprogramming in cancer cells represent a promising area in oncology research, offering new avenues for therapeutic intervention. While the 'Warburg effect' highlights the reliance of many tumors on aerobic gl...
Dysfunction of core clock genes regulates malignant phenotype and gemcitabine sensitivity of cholangiocarcinoma cells [0.03%]
核心时钟基因功能障碍调节胆管癌细胞恶性表型和吉西他滨敏感性
Yin Li,Aimin Zheng,Yangang Cui et al.
Yin Li et al.
The circadian clock governs daily rhythms in numerous physiological processes through precise regulation of gene expression and biochemical functions. Dysregulation of the circadian rhythm has been implicated in carcinogenesis and cancer pr...
Novel dibenzoylmethane derivative 2-allyl-1,3-diphenyl-1,3-propanedione: a safe and effective topical treatment for melanoma [0.03%]
新型二苯甲酮衍生物2-烯丙基-1,3-二苯基-1,3-丙二酮：一种安全有效的黑色素瘤外用治疗药物
Jefferson Viktor de Paula Barros Baeta,Maria Aparecida Braga Rocha E Oliveira,Fernada Rodrigues Nascimento et al.
Jefferson Viktor de Paula Barros Baeta et al.
This study investigated 2-allyl-1,3-diphenyl-1,3-propanedione (DPAP), a dibenzoylmethane derivative, as a potentially more effective and safer alternative to dacarbazine for melanoma treatment. The antitumor activity of DPAP was assessed th...
Progression of drug resistance or multiple primary lung cancer: a case report and literature review of a patient with mesenchymal-epithelial transition factor exon 14 skipping alterations lung adenocarcinoma [0.03%]
药物耐药进展或原发多病灶肺癌：带有间充质上皮转化因子第14外显子跳跃突变的肺腺癌病例报告及文献复习
Liang Gong,Lihang Zhou,Pan Yang et al.
Liang Gong et al.
Mesenchymal-epithelial transition factor (MET) exon 14 skipping alterations are rare mutations in non-small-cell lung cancer, associated with high malignancy and poor prognosis. This article presents a case of a patient diagnosed with advan...
α-Asarone attenuates tumor-associated macrophages-induced gemcitabine resistance in pancreatic carcinoma via the transforming growth factor-beta 1/growth factor independent 1 axis [0.03%]
α-艾asarone通过转化生长因子-β1/生长因子独立1轴缓解肿瘤相关巨噬细胞引起的胰腺癌吉西他滨耐药性
Jiaqi Yu,Yuzhe Xue,Zhaofeng Gao et al.
Jiaqi Yu et al.
Pancreatic cancer is characterized by aggressiveness and poor prognosis. The development of gemcitabine resistance, especially tumor-associated macrophage (TAM) -induced resistance in the tumor microenvironment, has greatly limited its ther...